Article Text

Download PDFPDF
Is MMR immunisation safe in chronic Idiopathic thrombocytopenic purpura?
  1. Anna C Bibby,
  2. Anna Farrell,
  3. Michelle Cummins,
  4. Michel Erlewyn-Lajeunesse
  1. Bristol Royal Hospital for Children, Bristol, UK
  1. Dr M Erlewyn-Lajeunesse, Paediatric Allergy, Immunology & Infectious Diseases, Southampton University Hospital, Tremona Road, Southampton SO16 6YD, UK; mich.lajeunesse{at}

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Idiopathic thrombocytopenic purpura (ITP) can occur after measles/mumps/rubella (MMR) immunisation, although its incidence is much lower than that after measles or rubella infection. MMR does not reactivate previous acute ITP.1 2 A second booster dose of MMR appears also to be safe in this regard.3 However, less is known about the safety of MMR in chronic ITP. We present three cases of children with chronic ITP whose illness was not exacerbated by immunisation (summarised in table 1).

View this table:
Table 1 Summary of three case studies

In the first case, a girl was diagnosed at 13 months old after admission for a petechial rash with a platelet count of 5×109/l. Despite trials of prednisolone, pulsed dexamethasone and intravenous immunoglobulins, her disease …

View Full Text


  • Funding: None.

  • Competing interests: None.